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In North Jutland County, Denmark, we investigated whether use of oral glucocorticoids was associated with an increased risk of
developing basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma (MM), and non-Hodgkin’s lymphoma
(NHL). From the Danish Cancer Registry we identified 5422 BCC, 935 SCC, 983 MM, and 481 NHL cases during 1989–2003. Using
risk-set sampling we selected four age- and gender-matched population controls for each case from the Civil Registration System.
Prescriptions for oral glucocorticoids before diagnosis were obtained from the Prescription Database of North Jutland County on the
basis of National Health Service data. We used conditional logistic regression to estimate incidence rate ratios (IRRs), adjusting for
chronic medical diseases (information about these were obtained from the National Patient Registry) and use of other
immunosuppressants. We found slightly elevated risk estimates for BCC (IRR, 1.15 (95% CI: 1.07–1.25)), SCC (IRR, 1.14 (95% CI:
0.94–1.39)), MM (IRR, 1.15 (95% CI: 0.94–1.41), and NHL (IRR, 1.11 (95% CI: 0.85–1.46)) among users of oral glucocorticoids. Our
study supports an overall association between glucocorticoid use and risk of BCC that cannot be explained by the presence of
chronic diseases or concomitant use of other immunosuppressants.
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Glucocorticoids were introduced in clinical practice in 1949 for the
treatment of rheumatoid arthritis (Le Vay and Loxton, 1949), since
their indications had expanded, and they are now used in many
specialties (Zoorob and Cender, 1998). Glucocorticoids exert
immunosuppressive effects, and there has been concern that their
use may promote immune-related cancers, such as basal cell
carcinoma (BCC), squamous cell carcinoma (SCC), malignant
melanoma (MM), and non-Hodgkin’s lymphoma (NHL). Despite
the extensive use of glucocorticoids and their carcinogenic
potential, epidemiological data are sparse. Two recent studies
conducted in Denmark and the USA reported increased risks of
skin cancer and NHL among users of systemic glucocorticoids who
were not transplant recipients. In both studies, use of glucocorti-
coids was associated with a two-fold increased risk of SCC and
NHL, and a modestly increased risk of BCC (Karagas et al, 2001;
Sorensen et al, 2004). However, two recent Swedish studies have
questioned whether these associations were causal (Askling et al,
2005; Baecklund et al, 2006). The first study found that patients
with polymyalgia rheumatica and giant cell arteritis did not have
an increased risk of lymphoma, although these patients were heavy
users of glucocorticoids (Askling et al, 2005). The second study
reported that the risk of lymphomas was associated with activity of
rheumatoid arthritis, rather than treatment with glucocorticoids
(Baecklund et al, 2006). Thus, it remains unclear whether the
increased risk of immune-related cancers stems from the
inflammatory activity of the chronic autoimmune diseases being
treated, other immunosuppressive drugs used to treat these
conditions, or the glucocorticoids per se.
To address these questions, we conducted a large population-
based case–control study in Denmark. We examined whether oral
glucocorticoid use was associated with an increased risk of skin
cancers and NHL, considering the chronic diseases being treated
and use of other immunosuppressive drugs.
MATERIALS AND METHODS
We conducted this population-based case–control study in North
Jutland County, with a population of about 500000 inhabitants
(approximately 9% of the Danish population) (Sorensen et al,
2008). Use of the unique 10-digit civil registry number, assigned to
all Danish residents (Frank, 2000), allowed us to link data on
cancer incidence, drug prescriptions, and hospital in- and
outpatient diagnoses.
From the Danish Cancer Registry (DCR), we identified all
patients registered with a diagnosis of skin cancer or NHL in North
Jutland County during 1989–2003. The DCR, established in 1943,
records primary cases of cancer on a nationwide basis with a high
degree of accuracy and completeness (Storm et al, 1997). Data in
the DCR include cancer type, site, morphology, and date of
diagnosis. Tumours are coded according to a modified version of
the seventh revision of the International Classification of Diseases
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y(ICD-7). Since 1978, tumours have also been classified according
to the first version of the International Classification of Diseases
for Oncology (ICD-O-1), which includes a four-digit code for
tumour morphology.
We used ICD-7 codes 1910–1919 to identify all BCC and SCC
cases registered in North Jutland County during 1989–2003. For
MM we used ICD-7 codes 1900–1909, and for NHL we used ICD-7
codes 2000–2009 and 2020–2029. We excluded patients with
cancer diagnosis or organ transplantation before the skin cancer or
NHL diagnosis. For BCC we included only patients with ICD-O-1
morphology codes 80903, 80913, 80923, 80933, and 81233. For SCC
we included only patients with ICD-O-1 codes 80513, 80703, 80713,
80743, 80763, 80943, and 80953. We identified 5422 BCC, 935 SCC,
983 MM, and 481 NHL cases.
The Civil Registration System contains information about the
vital status, date of death, and the area of residence of all Danish
residents, and is updated daily. Using the Civil Registration
System, we selected four population controls for each case. Cases
and controls were individually matched by age and gender on the
basis of risk-set sampling (Wacholder et al, 1992); that is, the
controls were sampled among county residents who were at risk of
a first skin cancer or NHL at the time the corresponding case was
diagnosed (index date assigned to controls). We excluded controls
with cancer diagnosis or organ transplantation before the index
date. A total of 29664 controls were identified. Using risk-set
sampling, the estimated exposure odds ratio in a case–control
design is an unbiased estimate of the incidence rate ratio (IRR) in a
corresponding cohort study (Szklo and Nieto, 2000).
Data on oral glucocorticoid prescriptions were obtained from
the Prescription Database of North Jutland County, a research
database based on National Health Service data (Gaist et al, 1997;
Nielsen et al, 1997). The database collects data on all prescriptions
filled by ambulatory patients and forwards data on reimbursable
medicines to the local regional Health Service section on a monthly
basis. This Health Service, in turn, refunds 50–75% of costs. The
database was established in 1989 (with complete coverage since
1991), and includes patients’ civil registry number as well as
information on the type of drug prescribed (according to the
Anatomical Therapeutical Chemical (ATC) classification system)
(Dukes, 1993), the date when the prescription was filled, packaging
size, the number of pills in each package, and the amount of drug
in each pill. Indications for drug use and dosing schedules are not
included. The ATC codes for glucocorticoids used in this study are
listed in Appendix 1.
Individuals with certain chronic medical conditions are more
likely to receive prescriptions for glucocorticoids. Some of these
conditions are also associated with an elevated risk of skin cancer
(Jensen et al, 2008) and NHL (Kinlen, 1992). To control for the
potentially confounding effects of chronic medical conditions, we
used the Danish National Registry of Patients to retrieve all hospital
diagnoses recorded among our study population from January 1,
1977 to December 31, 2003. Diagnoses are coded according to the
ICD-8 classification through 1993 and the ICD-10 thereafter. The
Danish National Registry of Patients contains information on all
non-psychiatric hospital admissions since 1977 (Andersen et al,
1999) and outpatient visits since 1995. We classified the diagnoses of
chronic diseases into the four categories listed in Appendix 2. In
addition, we retrieved information on prescriptions redeemed for
azathioprine (ATC code: L04AX01) and methotrexate (ATC code:
L01BA01), as use of these drugs has been associated with an
increased risk of skin cancer (Glover et al,1 9 9 7 ;J e n s e net al, 1999;
Marcen et al, 2003) and NHL (Kinlen, 1992).
Statistical analysis
For each subject, we identified all prescriptions for oral
glucocorticoids before the date of primary skin cancer or
NHL diagnosis, or before the corresponding index date for
the matched population control. We computed the total amount
of drug prescribed before the index date by multiplying
the package size, the number of pills in each package, and
the amount of drug in each pill. When the amount of drug
could not be calculated (for instance, due to missing infor-
mation in the prescription database), the average amount
dispensed for that particular drug was estimated. Average amounts
were applied to 13% of the identified prescriptions for oral
glucocorticoids.
Initially, we constructed contingency tables for cases and
controls by demographic characteristics (age and sex), anatomic
site of the skin tumour, prior hospitalisations for the selected
comorbid conditions, and previous prescriptions for azathioprine
and methotrexate. Three models were used for the various
combinations of oral glucocorticoid exposure and outcome (i.e.,
BCC, SCC, MM, and NHL). The first model treated the exposure as
a dichotomous variable (i.e., any/no prescription for glucocorti-
coids before the index date). The second model assumed a linear
effect of the exposure (i.e., as a continuous variable based on the
estimated milligrams of prescribed glucocorticoids, with ‘no
prescriptions before the index date’ as reference). The third model
was fitted to test for a nonlinear effect by treating the exposure as a
restricted cubic spline (Harre et al, 1988). Trend tests were used to
evaluate the statistical significance of the effect of increasing
amounts of prescribed oral glucocorticoids on the risk of these
cancers (dose–response relationship). P-values o0.05 were
considered statistically significant. We included the four chronic
disease categories, listed in Appendix 2, and prescriptions for
azathioprine and methotrexate as confounding factors. These
variables were included in the models as dichotomous variables,
that is, yes/no disease and yes/no prescription.
As cancer diagnoses might be differentially related to gluco-
corticoid use due to surveillance bias (Rothman, 2002), we also
conducted analyses excluding prescriptions issued within one year
of the skin cancer diagnosis or index date. These analyses might
also point to possible effects on the duration of glucocorticoid use.
We also conducted analyses stratified on the anatomic site of the
skin cancers (i.e., head and neck and other sites), to evaluate the
effects of glucocorticoids by level of sun exposure.
Non-reporting of diagnosed non-melanoma skin cancer (NMSC)
to the DCR has been estimated to range from 12 to 40% (Frentz,
1996; Jensen et al, 2007). Therefore, we conducted a sensitivity
analysis (Fox et al, 2005a; Greenland, 2005) to explore the
magnitude of effects of the non-reporting of NMSC cases on our
results. We expected the non-reporting to be differential between
users and non-users of glucocorticoids; NMSC is rarely fatal, and
therefore in severely diseased patients (such as users of
glucocorticoids) clinicians could potentially deem these cancers
trivial and thereby omit registration. We used the SAS-macro
written by Fox, Lash and Greenland, which was adapted to perform
conditional logistic regression (Fox et al, 2005b).
This study was approved by the Danish Protection Agency
(Record no. 2004-41-4693). The statistical software packages R,
version 2.4.1, and SAS, version 9.1 (SAS Institute Inc., Cary, NC),
were used for all statistical analyses.
RESULTS
The characteristics of cancer cases and controls are presented in
Table 1. The median age was 68 years among BCC, 77 years among
SCC, 58 years among MM, and 64 years among NHL cases. The
majority of the SCC tumours were located on chronically sun-
exposed sites, that is head and neck, in contrast to MMs, of which
only 16% were located on the head and neck. More NHL cases than
controls had a history of hospitalisation for a chronic inflamma-
tory disease, such as a connective tissue disease, inflammatory
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conditions was similar among skin cancer cases and their controls.
Use of oral glucocorticoids was slightly more frequent among
BCC, SCC, MM, and NHL cases compared with controls. Adjusted
IRRs were 1.15 (95% CI: 1.07–1.25) for BCC, 1.14 (95% CI: 0.94–
1.39) for SCC, 1.15 (95% CI: 0.94–1.41) for MM, and 1.11 (95% CI:
0.85–1.46) for NHL (Table 2). For NHL, the risk increased linearly
with the amount of glucocorticoids prescribed (IRR risk increase
per 10000mg¼2.26 (95% CI: 1.20–4.26), P¼0.01). The restricted
cubic spline showed the best fit to the data for SCC, and we found a
statistically significant increased risk of SCC with increasing
amounts of glucocorticoids prescribed (cumulative IRR per
10000mg¼7.40 (95% CI: 1.80–30.4), P¼0.001, data not shown).
We found no dose–response relationship between glucocorticoid
Table 1 Characteristics among cases with basal cell carcinoma, squamous cell carcinoma, malignant melanoma, and non-Hodgkin’s lymphoma and
controls (restricted to those cases with no history of organ transplants or cancer before the actual cancer under study)
Basal cell carcinoma Squamous cell carcinoma Malignant melanoma Non-Hodgkin’s lymphoma
Cases
(N¼5422)
Controls
(N¼22457)
Cases
(N¼935)
Controls
(N¼4166)
Cases
(N¼983)
Controls
(N¼4406)
Cases
(N¼481)
Controls
(N¼2004)
Demographic characteristics
Age (median) 68 68 77 77 58 58 64 64
Gender: male 50% 50% 67% 68% 41% 42% 53% 54%
Anatomic site of skin cancer
Head and neck 54% — 64% — 16% — —
Other sites 46% — 36% — 84% — —
Comorbidities/history of hospitalisation
Chronic pulmonary disease 299 (6%) 1234 (6%) 65 (7%) 306 (7%) 25 (3%) 187 (4%) 32 (7%) 100 (5%)
Connective tissue disease 123 (2%) 409 (2%) 33 (4%) 74 (2%) 16 (2%) 76 (2%) 13 (3%) 30 (2%)
Inflammatory bowel disease 33 (0.6%) 136 (0.6%) 5 (0.5%) 20 (0.5%) 5 (0.5%) 33 (0.8%) 5 (1%) 9 (0.5%)
Allergy 135 (2%) 432 (2%) 24 (3%) 91 (2%) 13 (1%) 90 (2%) 9 (2%) 27 (1%)
Other drug use/prior drug prescriptions:
Methotrexate 30 (0.6%) 69 (0.3%) 2 (0.2%) 11 (0.2%) 4 (0.4%) 16 (0.4%) 2 (0.4%) 5 (0.3%)
Azathioprine 17 (0.3%) 57 (0.3%) 10 (1%) 8 (0.2%) 1 (0.1%) 9 (0.2%) 1 (0.2%) 3 (0.2%)
Table 2 Use of glucocorticoids and risk of skin cancer and non-Hodgkin’s lymphoma
All prescriptions before diagnosis date
Prescriptions41
year before
diagnosis date
Prescriptions45
years before
diagnosis date
Cases N
(%)
Controls
N (%)
IRR age and
gender adjusted
(95% CI)
IRR
adjusted
a
(95% CI)
P-value for
trend test
(adjusted)
IRR adjusted
a
(95% CI)
IRR adjusted
a
(95% CI)
Basal cell carcinoma
No prescriptions 4300
(79%)
18278
(81%)
1.00 1.00 — 1.00 1.00
Any prescription 1122
(21%)
4179 (19%) 1.17 (1.08–1.27) 1.15 (1.07–1.25) 1.17 (1.08–1.28) 1.22 (1.09–1.36)
Risk increase per 10000mg
b 1.10 (0.98–1.22) 1.07 (0.96–1.20) 0.2
Squamous cell carcinoma
No prescriptions 732 (78%) 3379 (81%) 1.00 1.00 — 1.00 1.00
Any prescription 203 (22%) 787 (19%) 1.21 (1.01–1.46) 1.14 (0.94–1.39) 1.09 (0.88–1.34) 1.11 (0.85–1.45)
Risk increase per 10000mg
b 1.23 (0.98–1.54) 1.12 (0.88–1.43)
c 0.4
Malignant melanoma
No prescriptions 820 (83%) 3696 (84%) 1.00 1.00 — 1.00 1.00
Any prescription 163 (17%) 710 (16%) 1.09 (0.90–1.33) 1.15 (0.94–1.41) 1.12 (0.90–1.39) 1.00 (0.75–1.36)
Risk increase per 10000mg
b 1.11 (0.91–1.37) 0.94 (0.65–1.37) 0.8
Non-Hodgkin’s lymphoma
No prescriptions 383 (80%) 1648 (82%) 1.00 1.00 — 1.00 1.00
Any prescription 98 (20%) 356 (18%) 1.20 (0.92–1.56) 1.11 (0.85–1.46) 1.08 (0.81–1.44) 1.04 (0.71–1.54)
Risk increase per 10000mg
b 2.51 (1.41–4.49) 2.26 (1.20–4.26) 0.01
CI¼confidence interval; IRR¼incidence rate ratio; SCC¼squamous cell carcinoma.
aConditional logistic regression was used to estimate IRRs and 95% CI, adjustments were
made for a prior hospitalisation for selected chronic diseases and use of methotrexate and azathioprine.
bIn this model we assumed a linear effect of the exposure.
cThe restricted
cubic spline showed the best fit to the data (Harre et al, 1988), with a statistically significant increased risk of SCC with increasing amounts of glucocorticoids prescribed
(cumulative IRR per 10000mg¼7.40 (95% CI: 1.80–30.4), P¼0.001).
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model (Table 2).
We found a slight trend of increasing risk of BCC among the
users of glucocorticoids with longer duration of use, with IRRs
increasing to 1.17 (95% CI: 1.08–1.28) among recorded users of
more than 1 year, and to 1.22 (95% CI: 1.09–1.36) among recorded
users of more than 5 years before the diagnosis date (Table 2). This
pattern was not seen for SCC, MM, or NHL.
Among glucocorticoid users, the risk of a BCC located on the
head and neck was slightly higher (IRR 1.23 (95% CI: 1.11–1.37))
than the risk of BCC at other anatomic sites (IRR 1.06 (95% CI:
0.94–1.20)). Such pattern was not seen for SCC and MM (data not
shown).
The sensitivity analyses showed that if we had corrected for a
differential under-ascertainment of NMSC cases from 5 to 45%
(trapezoidal distribution) among users of glucocorticoids, the
estimates for NMSC risk should have increased by a factor of 1.3
(Table 3).
DISCUSSION
We found a positive association between use of oral glucocorti-
coids and risk of BCC. The risk of BCC increased slightly with
duration of use and was higher for tumours located on chronic
sun-exposed areas, which support a causal explanation for our
findings. We further detected a dose-related trend of increasing
risk of SCC and NHL with increasing amount of glucocorticoid
prescribed. However, these dose–response-related risk estimates
had very limited statistical precision because they were based on
low proportions of cases and should therefore be interpreted with
caution. Our findings agree with the result of an earlier study in
North Jutland showing a positive association between number of
prescriptions for oral glucocorticoids and risk of BCC, SCC, and
NHL (Sorensen et al, 2004). However, we did not find the same
convincing association between oral glucocorticoid use, and risk of
SCC and NHL (Sorensen et al, 2004). A possible explanation for
this discrepancy may be that we excluded persons with prior
cancers and organ transplants from this analysis. We also adjusted
for other medical conditions and medications that may have
confounded the results of the earlier study (Sorensen et al, 2004).
Our study has several strengths. The uniformly organised
Danish health care system allows a truly population-based design.
Data on oral glucocorticoids were collected prospectively and
independent of the cancer data, limiting the potential for recall
bias found in interview-based studies (Karagas, 1993). Moreover,
by excluding glucocorticoid use within 1 and 5 years of the cancer
diagnosis, we were able to assess the potential effect of a
surveillance bias on our results. This surveillance bias refers to
the possibility that users of oral glucocorticoids are under closer
surveillance and probably receive more medical attention than
non-users, and thus are expected to have a greater likelihood of
having a cancer diagnosed. We found this to be a slight bias.
Among the limitations of our study is the use of data on filled
prescription as a surrogate for actual use of the drugs. This could
lead to misclassification of some non-users as users (non-
adherence to the drug), leading to conservative risk estimates.
However, the users had redeemed and paid for the prescription,
and therefore this bias is likely to be small. Moreover, we may have
under-adjusted for the chronic medical conditions that we
considered to be confounding factors. Many patients suffering
from these conditions are never referred to hospitals but are
followed by their general practitioner. Another source of bias is left
truncation of data from the Danish National Registry of Patients,
which only dates back to 1977, and the Prescription Database, to
1989. Therefore, we may have missed some information on chronic
diseases as confounding factors and exposures to oral glucocorti-
coids. This misclassification would likely be differential among
cases and controls, as we would expect current users of oral
glucocorticoids to have had more chronic diseases in the past, and
a greater likelihood of earlier prescriptions of oral glucocorticoids.
Thus, the resulting bias could lead us to either over- or
underestimate our risk estimates. Another source of potential bias
is that records of NMSC in particular may be unreported to the
DCR (Frentz, 1996; Frentz and Olsen, 1999). As NMSC is rarely
fatal, in severely diseased patients, such as glucocorticoid users,
clinicians could potentially deem the NMSC trivial, and therefore
pay less medical attention to them. As shown by the sensitivity
analyses, this potential under-ascertainment of NMSC cases using
glucocorticoids in our case–control study could have led to a
substantial underestimation of the overall effect of glucocorticoid
use on the risk of SCC and BCC.
Data such as skin phenotype (i.e., skin sensitivity to sunlight
and sun exposure) and sun bathing habits were unavailable
in this registry-based study. In addition, there may be some
residual confounding from history of chronic diseases, as we were
unable to adjust for the inflammatory activity (i.e., severity) of the
individual chronic diseases. Consequently, we could not address
these factors and other potential confounding effects on skin
cancer, and NHL risk among patients taking oral glucocorticoids.
The mechanisms behind our findings are not entirely clear, but our
results support the hypothesis that immunosuppression by oral
glucocorticoids is a risk factor for BCC. Our results are unlikely to
be explained by confounding by the presence of chronic diseases
or use of other immunosuppressants in conjunction with
glucocorticoids.
Table 3 Probabilistic sensitivity analyses correcting for differential non-reporting of cases with NMSC with sensitivity and specificity drawn from
trapezoidal and uniform distributions
Analysis
Basal cell carcinoma
a Squamous cell carcinoma
IRR 2.5
percentile
IRR median
estimate
IRR 97.5
percentile
IRR 2.5
percentile
IRR median
estimate
IRR 97.5
percentile
Conventional analysis 1.07 1.15 1.25 0.94 1.15 1.40
Differential sensitivity
analysis–systematic error
1.17 1.45 1.92 1.15 1.47 2.00
Differential sensitivity
analysis–systematic and
random error
1.14 1.45 1.94 1.06 1.48 2.16
BCC¼basal cell carcinoma; IRR¼incidence rate ratios; NMSC¼non-melanoma skin cancer. Sensitivity among cases using glucocorticoids: Trapezodial distribution
(minimum¼0.55, mode 1¼0.6, mode 2¼0.9, maximum¼0.95). Sensitivity among cases not using glucocorticoids: Uniform distribution (minimum¼0.8, maximum¼1.0).
Specificity among non-cases: Uniform distribution (minimum¼0.95, maximum¼1.0).
aThe sensitivity analysis should be cautiously interpreted for risk of BCC among oral
glucocorticoid users, because the SAS-macro did not converge after approximately 25000 iterations. Therefore, the macro was reran and stopped after 5000 iterations.
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Appendix 1
The ATC codes for oral glucocorticoids
Glucocorticoids ATC codes
Budenoside A07EA06
Hydrocortisone A07EA02, H02AB09
Prednisolone A07EA01, H02AB06
Prednisone H02AB07
Betamethasone H02AB01
Methylprednisolone H02AB04
Triamcinolone H02AB08
ATC¼anatomical therapeutical chemical.
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Classification of chronic diseases and ICD-8 and ICD-10 diagnoses codes
Disease category Diseases ICD-8 ICD-10
Chronic pulmonary disease Emphysema and chronic obstructive lung disease 490–493; 515–518 J40–J47; J60–J67; J68.4; J70.1; J70.3;
J84.1; J92.0; J96.1; J98.2; J98.3
Connective tissue disease Diffuse connective tissue disease, Sjoegren’s syndrome,
rheumatoid arthritis and other inflammatory
polyarthropathies and polymyalgia rheumatica
712; 716; 734; 446; 135.99 M05; M06; M08; M09; M30–M36; D86
Inflammatory Colitis ulcerosa 561 K50
Bowel diseases Crohn’s disease 563 K51
Allergy Atopic dermatitis 502; 493; J30, J45–J47
Asthma 692.59; L20, K52.2
Food allergy 691; 692 T78
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